Primary Drug Name: Advair
(Advair Diskus)
Generic name: fluticasone propionate and salmeterol xinafoate
What is Advair Diskus Asthma Medication?
Advair Diskus is the first and only product approved by the FDA
that combines an inhaled corticosteroid and an inhaled long-acting
bronchodilator in one easy-to-use device. Advair Diskus does not
replace fast-acting inhalers for sudden symptoms.
Advair Diskus effectively treats the two main components of asthma
at the same time: constriction, the tightening of the muscles around
the airways, and inflammation, the swelling and irritation of the
airways. Constriction and inflammation cause the airways to narrow
and reduce airflow into the lungs, which may result in symptoms
such as wheezing, coughing, chest tightness, or shortness of breath.
The combination of fluticasone and salmeterol (Advair) is used to prevent wheezing, shortness of breath, and breathing difficulties caused by asthma. Advair/Fluticasone is in a class of medications called steroids. Advair works by reducing swelling in the airways. Advair/Salmeterol is in a class of medications called long-acting beta-agonists. Advair works by relaxing and opening air passages in the lungs.
How should Advair Asthma
Medication be Used?
Help take control of your asthma with Advair Diskus. Taking a dose
of Advair Diskus requires the following three simple steps: Open,
Click, Inhale.* (Please see complete Patient Instructions for Use
provided with every Advair Diskus.)
1. OPEN
Hold the DISKUS in one hand and put the thumb of your other hand
on the thumbgrip. Push your thumb away from you as far as it will
go until the mouthpiece appears and snaps into position.
2. CLICK
Hold the DISKUS in a level, horizontal position with the mouthpiece
towards you. Slide the lever away from you as far as it will go
until it clicks. The DISKUS is now ready to use.
Every time the lever is pushed back, a dose is ready to be inhaled.
This is shown by a decrease in numbers on the dose counter.
To avoid releasing or wasting doses:
• Do not close the DISKUS.
• Do not tilt the DISKUS.
• Do not play with the lever.
• Do not advance the lever more than once.
3. INHALE
Before inhaling your dose of Advair Diskus, breathe out as far as
is comfortable, holding the DISKUS level and away from your mouth.
Remember, never breathe out into the DISKUS mouthpiece.
Put the mouthpiece to your lips. Breathe in quickly and deeply through
the Advair Diskus, not through your nose.
Remove the DISKUS from your mouth. Hold your breath for about 10
seconds, or for as long as is comfortable. Breathe out slowly.
*CLOSE the DISKUS when you are finished taking a dose so that the
DISKUS will be ready for you to take your next dose. Put your thumb
on the thumbgrip and slide the thumbgrip back towards you as far
as it will go. The DISKUS will click shut. The lever will automatically
return to its original position. The DISKUS is now ready for you
to take your next scheduled dose, due in approximately 12 hours.
(Repeat steps 1 through 3.)
REMEMBER:
• Never exhale into the DISKUS.
• Never attempt to take the DISKUS apart.
• Always activate and use the DISKUS in a level, horizontal
position.
• After inhalation, rinse your mouth with water without swallowing.
• Never wash the mouthpiece or any part of the DISKUS. KEEP
IT DRY.
• Always keep the DISKUS in a dry place.
• Never take an extra dose, even if you feel you did not receive
a dose.
Advair Precautions
General: Cardiovascular Effects: Cardiovascular and central nervous
system effects seen with all sympathomimetic drugs (e.g., increased
blood pressure, heart rate, excitement) can occur after use of salmeterol,
a component of Advair Diskus, and may require discontinuation of
Advair Diskus. Advair Diskus, like all medications containing sympathomimetic
amines, should be used with caution in patients with cardiovascular
disorders, especially coronary insufficiency, cardiac arrhythmias,
and hypertension; in patients with convulsive disorders or thyrotoxicosis;
and in patients who are unusually responsive to sympathomimetic
amines.
As has been described with other beta-adrenergic agonist bronchodilators,
clinically significant changes in ECGs have been seen infrequently
in individual patients in controlled clinical studies with Advair Diskus and salmeterol. Clinically significant changes in systolic
and/or diastolic blood pressure and pulse rate have been seen infrequently
in individual patients in controlled clinical studies with salmeterol,
a component of Advair Diskus.
Metabolic and Other Effects: Long-term use of orally inhaled corticosteroids
may affect normal bone metabolism, resulting in a loss of bone mineral
density (BMD). A 2-year study of 160 patients (females 18 to 40
and males 18 to 50 years of age) with asthma receiving chlorofluorocarbon-propelled
fluticasone propionate inhalation aerosol 88 or 440 mcg twice daily
demonstrated no statistically significant changes in BMD at any
time point (24, 52, 76, and 104 weeks of double-blind treatment)
as assessed by dual-energy x-ray absorptiometry at lumbar region
L1 through L4. Long-term treatment effects of fluticasone propionate
on BMD in the COPD population have not been studied.
In patients with major risk factors for decreased bone mineral content,
such as tobacco use, advanced age, sedentary lifestyle, poor nutrition,
family history of osteoporosis, or chronic use of drugs that can
reduce bone mass (e.g., anticonvulsants and corticosteroids), Advair Diskus may pose an additional risk. Since patients with COPD often
have multiple risk factors for reduced BMD, assessment of BMD is
recommended, including prior to instituting Advair Diskus 250/50
and periodically thereafter. If significant reductions in BMD are
seen and Advair Diskus 250/50 is still considered medically important
for that patient’s COPD therapy, use of medication to treat
or prevent osteoporosis should be strongly considered. Advair Diskus
250/50 mcg twice daily is the only approved dosage for the treatment
of COPD associated with chronic bronchitis, and higher doses, including
Advair Diskus 500/50, are not recommended.
Glaucoma, increased intraocular pressure, and cataracts have been
reported in patients with asthma and COPD following the long-term
administration of inhaled corticosteroids, including fluticasone
propionate, a component of Advair Diskus; therefore, regular eye
examinations should be considered.
Lower respiratory tract infections, including pneumonia, have been
reported following the inhaled administration of corticosteroids,
including fluticasone propionate and Advair Diskus.
Doses of the related beta2-adrenoceptor agonist albuterol, when
administered intravenously, have been reported to aggravate preexisting
diabetes mellitus and ketoacidosis. Beta-adrenergic agonist medications
may produce significant hypokalemia in some patients, possibly through
intracellular shunting, which has the potential to produce adverse
cardiovascular effects. The decrease in serum potassium is usually
transient, not requiring supplementation.
Clinically significant changes in blood glucose and/or serum potassium
were seen infrequently during clinical studies with Advair Diskus
at recommended doses.
During withdrawal from oral corticosteroids, some patients may experience
symptoms of systemically active corticosteroid withdrawal, e.g.,
joint and/or muscular pain, lassitude, and depression, despite maintenance
or even improvement of respiratory function.
Fluticasone propionate, a component of Advair Diskus, will often
help control asthma symptoms with less suppression of HPA function
than therapeutically equivalent oral doses of prednisone. Since
fluticasone propionate is absorbed into the circulation and can
be systemically active at higher doses, the beneficial effects of
Advair Diskus in minimizing HPA dysfunction may be expected only
when recommended dosages are not exceeded and individual patients
are titrated to the lowest effective dose. A relationship between
plasma levels of fluticasone propionate and inhibitory effects on
stimulated cortisol production has been shown after 4 weeks of treatment
with fluticasone propionate inhalation aerosol. Since individual
sensitivity to effects on cortisol production exists, physicians
should consider this information when prescribing Advair Diskus.
Because of the possibility of systemic absorption of inhaled corticosteroids,
patients treated with Advair Diskus should be observed carefully
for any evidence of systemic corticosteroid effects. Particular
care should be taken in observing patients postoperatively or during
periods of stress for evidence of inadequate adrenal response.
It is possible that systemic corticosteroid effects such as hypercorticism
and adrenal suppression (including adrenal crisis) may appear in
a small number of patients, particularly when fluticasone propionate
is administered at higher than recommended doses over prolonged
periods of time. If such effects occur, the dosage of Advair Diskus
should be reduced slowly, consistent with accepted procedures for
reducing systemic corticosteroids and for management of asthma symptoms.
Orally inhaled corticosteroids may cause a reduction in growth velocity
when administered to pediatric patients. Patients should be maintained
on the lowest strength of Advair Diskus that effectively controls
their asthma.
The long-term effects of Advair Diskus in human subjects are not
fully known. In particular, the effects resulting from chronic use
of fluticasone propionate on developmental or immunologic processes
in the mouth, pharynx, trachea, and lung are unknown. Some patients
have received inhaled fluticasone propionate on a continuous basis
for periods of 3 years or longer. In clinical studies in patients
with asthma treated for 2 years with inhaled fluticasone propionate,
no apparent differences in the type or severity of adverse reactions
were observed after long- versus short-term treatment.
In clinical studies with Advair Diskus, the development of localized
infections of the pharynx with Candida albicans has occurred. When
such an infection develops, it should be treated with appropriate
local or systemic (i.e., oral antifungal) therapy while remaining
on treatment with Advair Diskus, but at times therapy with Advair Diskus may need to be interrupted.
Inhaled corticosteroids should be used with caution, if at all,
in patients with active or quiescent tuberculosis infections of
the respiratory tract; untreated systemic fungal, bacterial, viral,
or parasitic infections; or ocular herpes simplex.
Eosinophilic Conditions: In rare cases, patients on inhaled fluticasone
propionate, a component of Advair Diskus, may present with systemic
eosinophilic conditions, with some patients presenting with clinical
features of vasculitis consistent with Churg-Strauss syndrome, a
condition that is often treated with systemic corticosteroid therapy.
These events usually, but not always, have been associated with
the reduction and/or withdrawal of oral corticosteroid therapy following
the introduction of fluticasone propionate. Cases of serious eosinophilic
conditions have also been reported with other inhaled corticosteroids
in this clinical setting. Physicians should be alert to eosinophilia,
vasculitic rash, worsening pulmonary symptoms, cardiac complications,
and/or neuropathy presenting in their patients. A causal relationship
between fluticasone propionate and these underlying conditions has
not been established (see ADVERSE REACTIONS: Observed During Clinical
Practice: Eosinophilic Conditions).
Chronic Obstructive Pulmonary Disease: Advair Diskus 250/50 twice
daily is the only dosage recommended for the treatment of airflow
obstruction in patients with COPD associated with chronic bronchitis.
Higher doses, including Advair Diskus 500/50, are not recommended,
as no additional improvement in lung function (defined by predose
and postdose FEV1) was observed in clinical trials and higher doses
of corticosteroids increase the risk of systemic effects.
The benefit of treatment of patients with COPD associated with chronic
bronchitis with Advair Diskus 250/50 for periods longer than 6 months
has not been evaluated. Patients who are treated with Advair Diskus
250/50 for COPD associated with chronic bronchitis for periods longer
than 6 months should be reevaluated periodically to assess the continuing
benefits and potential risks of treatment.
What are Advair Side Effects?
Advair Side Effects that may occur while taking ADVAIR include
hoarseness (dysphonia), throat irritation, headache, cough, or dry
mouth or throat. If they continue or are bothersome, check with
your doctor.
CHECK WITH YOUR DOCTOR IMMEDIATELY if you experience
white patches on tongue or mouth, or if your mouth/tongue becomes
swollen and painful. CONTACT YOUR DOCTOR IMMEDIATELY if you experience
any of the following unlikely but serious side effects: weight gain,
vision changes, trouble sleeping, tremors, seizures, severe muscle
weakness or cramping, fast/irregular heartbeat, numbness or tingling
in hands or feet, chest pain, or worsening of asthma symptoms (e.g.,
increased difficulty breathing, wheezing, coughing).
AN ALLERGIC
REACTION to ADVAIR is unlikely but seek immediate medical attention
if it occurs. Symptoms of an allergic reaction include rash, itching,
swelling, dizziness, or trouble breathing. Rarely, your wheezing
might actually increase immediately after using this medicine (paradoxical
bronchospasm). If this occurs, use your "quick-relief"
inhaler (such as albuterol). Seek immediate medical attention if
your breathing does not improve at that time. If you notice other
advair side effects effects not listed above, contact your doctor,
nurse, or pharmacist.
Advair Diskus Dosage and Administration
Advair Diskus should be administered by the orally inhaled route
inhalation, the patient should rinse the mouth with water without
swallowing. Advair Diskus should not be used for transferring patients
from systemic corticosteroid therapy.
Asthma: Advair Diskus is available in 3 strengths, Advair Diskus
100/50, Advair Diskus 250/50, and Advair Diskus 500/50, containing
100, 250, and 500 mcg of fluticasone propionate, respectively, and
50 mcg of salmeterol per inhalation.
For patients 12 years of age and older, the dosage is 1 inhalation
twice daily (morning and evening, approximately 12 hours apart).
The recommended starting dosages for Advair Diskus are based upon
patients’ current asthma therapy.
•For patients who are not currently on an inhaled corticosteroid,
whose disease severity warrants treatment with 2 maintenance therapies,
including patients on non-corticosteroid maintenance therapy, the
recommended starting dosage is Advair Diskus 100/50 twice daily.
• For patients on an inhaled corticosteroid, the maximum recommended
dosage is Advair Diskus 500/50 twice daily.
For all patients it is desirable to titrate to the lowest effective
strength after adequate asthma stability is achieved.
Advair Diskus should be administered twice daily every day. More
frequent administration (more than twice daily) or a higher number
of inhalations (more than 1 inhalation twice daily) of the prescribed
strength of Advair Diskus is not recommended as some patients are
more likely to experience adverse effects with higher doses of salmeterol.
The safety and efficacy of Advair Diskus when administered in excess
of recommended doses have not been established.
If symptoms arise in the period between doses, an inhaled, short-acting
beta2-agonist should be taken for immediate relief.
Patients who are receiving Advair Diskus twice daily should not
use additional salmeterol or other inhaled, long-acting beta2-agonists
(e.g., formoterol) for prevention of EIB, or for any other reason.
Improvement in asthma control following inhaled administration of
Advair Diskus can occur within 30 minutes of beginning treatment,
although maximum benefit may not be achieved for 1 week or longer
after starting treatment. Individual patients will experience a
variable time to onset and degree of symptom relief.
For patients who do not respond adequately to the starting dosage
after 2 weeks of therapy, replacing the current strength of Advair Diskus with a higher strength may provide additional improvement
in asthma control.
If a previously effective dosage regimen of Advair Diskus fails
to provide adequate improvement in asthma control, the therapeutic
regimen should be reevaluated and additional therapeutic options,
e.g., replacing the current strength of Advair Diskus with a higher
strength, adding additional inhaled corticosteroid, or initiating
oral corticosteroids, should be considered.
Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis:
The dosage for adults is 1 inhalation (250/50 mcg) twice daily (morning
and evening, approximately 12 hours apart).
Advair Diskus 250/50 mcg twice daily is the only approved dosage
for the treatment of COPD associated with chronic bronchitis. Higher
doses, including Advair Diskus 500/50, are not recommended, as no
additional improvement in lung function was observed in clinical
trials and higher doses of corticosteroids increase the risk of
systemic effects.
If shortness of breath occurs in the period between doses, an inhaled,
short-acting beta2-agonist should be taken for immediate relief.
Patients who are receiving Advair Diskus twice daily should not
use additional salmeterol or other inhaled, long-acting beta2-agonists
(e.g., formoterol) for the maintenance treatment of COPD or for
any other reason.
Geriatric Use: In studies where geriatric patients (65 years of
age or older, see PRECAUTIONS: Geriatric Use) have been treated
with Advair Diskus, efficacy and safety did not differ from that
in younger patients. Based on available data for Advair Diskus and
its active components, no dosage adjustment is recommended.
Advair Mechanism of Action
Advair Diskus contains 2 medicines, fluticasone propionate (a synthetic
corticosteroid) and salmeterol xinafoate (a long-acting bronchodilator),
which work in different ways in the lungs to improve lung function
and symptoms in patients with asthma. Fluticasone propionate is
used to reduce the airway inflammation and salmeterol a long-acting
bronchodilator helps prevent and relieve bronchospasm, making it
easier to breathe.
Fluticasone propionate and salmeterol in Advair Diskus work together
to improve lung function in patients with COPD associated with chronic
bronchitis.
Advair Asthma Medication Warnings
1. Advair Diskus SHOULD NOT BE USED FOR TRANSFERRING PATIENTS FROM
SYSTEMIC CORTICOSTEROID THERAPY. Particular care is needed for patients
who have been transferred from systemically active corticosteroids
to inhaled corticosteroids because deaths due to adrenal insufficiency
have occurred in patients with asthma during and after transfer
from systemic corticosteroids to less systemically available inhaled
corticosteroids. After withdrawal from systemic corticosteroids,
a number of months are required for recovery of HPA function.
Patients who have been previously maintained on 20 mg or more per
day of prednisone (or its equivalent) may be most susceptible, particularly
when their systemic corticosteroids have been almost completely
withdrawn. During this period of HPA suppression, patients may exhibit
signs and symptoms of adrenal insufficiency when exposed to trauma,
surgery, or infection (particularly gastroenteritis) or other conditions
associated with severe electrolyte loss. Although inhaled corticosteroids
may provide control of asthma symptoms during these episodes, in
recommended doses they supply less than normal physiological amounts
of glucocorticoid systemically and do NOT provide the mineralocorticoid
activity that is necessary for coping with these emergencies.
During periods of stress or a severe asthma attack, patients who
have been withdrawn from systemic corticosteroids should be instructed
to resume oral corticosteroids (in large doses) immediately and
to contact their physicians for further instruction. These patients
should also be instructed to carry a warning card indicating that
they may need supplementary systemic corticosteroids during periods
of stress or a severe asthma attack.
2. Advair Diskus SHOULD NOT BE INITIATED IN PATIENTS DURING RAPIDLY
DETERIORATING OR POTENTIALLY LIFE-THREATENING EPISODES OF ASTHMA.
Serious acute respiratory events, including fatalities, have been
reported both in the United States and worldwide when salmeterol,
a component of Advair Diskus, has been initiated in patients with
significantly worsening or acutely deteriorating asthma. In most
cases, these have occurred in patients with severe asthma (e.g.,
patients with a history of corticosteroid dependence, low pulmonary
function, intubation, mechanical ventilation, frequent hospitalizations,
or previous life-threatening acute asthma exacerbations) and/or
in some patients in whom asthma has been acutely deteriorating (e.g.,
unresponsive to usual medications; increasing need for inhaled,
short-acting beta2-agonists; increasing need for systemic corticosteroids;
significant increase in symptoms; recent emergency room visits;
sudden or progressive deterioration in pulmonary function). However,
they have occurred in a few patients with less severe asthma as
well. It was not possible from these reports to determine whether
salmeterol contributed to these events or simply failed to relieve
the deteriorating asthma.
3. Drug Interaction With Ritonavir: A drug interaction study in
healthy subjects has shown that ritonavir (a highly potent cytochrome
P450 3A4 inhibitor) can significantly increase plasma fluticasone
propionate exposure, resulting in significantly reduced serum cortisol
concentrations (see CLINICAL PHARMACOLOGY: Pharmacokinetics: Fluticasone
Propionate: Drug Interactions and PRECAUTIONS: Drug Interactions:
Inhibitors of Cytochrome P450). During postmarketing use, there
have been reports of clinically significant drug interactions in
patients receiving fluticasone propionate and ritonavir, resulting
in systemic corticosteroid effects including Cushing syndrome and
adrenal suppression. Therefore, coadministration of fluticasone
propionate and ritonavir is not recommended unless the potential
benefit to the patient outweighs the risk of systemic corticosteroid
side effects.
4. Do Not Use Advair Diskus to Treat Acute Symptoms: An inhaled,
short-acting beta2-agonist, not Advair Diskus, should be used to
relieve acute symptoms of shortness of breath. When prescribing
Advair Diskus, the physician must also provide the patient with
an inhaled, short-acting beta2-agonist (e.g., albuterol) for treatment
of shortness of breath that occurs acutely, despite regular twice-daily
(morning and evening) use of Advair Diskus.
When beginning treatment with Advair Diskus, patients who have been
taking oral or inhaled, short-acting beta2-agonists on a regular
basis (e.g., 4 times a day) should be instructed to discontinue
the regular use of these drugs. For patients on Advair Diskus, inhaled,
short-acting beta2-agonists should only be used for symptomatic
relief of acute symptoms of shortness of breath (see PRECAUTIONS:
Information for Patients).
5. Watch for Increasing Use of Inhaled, Short-Acting Beta2-Agonists,
Which Is a Marker of Deteriorating Asthma: Asthma may deteriorate
acutely over a period of hours or chronically over several days
or longer. If the patient’s inhaled, short-acting beta2-agonist
becomes less effective, the patient needs more inhalations than
usual, or the patient develops a significant decrease in lung function,
this may be a marker of destabilization of the disease. In this
setting, the patient requires immediate reevaluation with reassessment
of the treatment regimen, giving special consideration to the possible
need for replacing the current strength of Advair Diskus with a
higher strength, adding additional inhaled corticosteroid, or initiating
systemic corticosteroids. Patients should not use more than 1 inhalation
twice daily (morning and evening) of Advair Diskus.
6. Do Not Use an Inhaled, Long-Acting Beta2-Agonist in Conjunction
With Advair Diskus: Patients who are receiving Advair Diskus twice
daily should not use additional salmeterol or other inhaled, long-acting
beta2-agonists (e.g., formoterol) for prevention of exercise-induced
bronchospasm (EIB) or the maintenance treatment of asthma or the
maintenance treatment of bronchospasm associated with COPD. Additional
benefit would not be gained from using supplemental salmeterol or
formoterol for prevention of EIB since Advair Diskus already contains
an inhaled, long-acting beta2-agonist.
7. Do Not Exceed Recommended Dosage: Advair Diskus should not be
used more often or at higher doses than recommended. Fatalities
have been reported in association with excessive use of inhaled
sympathomimetic drugs. Large doses of inhaled or oral salmeterol
(12 to 20 times the recommended dose) have been associated with
clinically significant prolongation of the QTc interval, which has
the potential for producing ventricular arrhythmias.
8. Paradoxical Bronchospasm: As with other inhaled asthma and COPD
medications, Advair Diskus can produce paradoxical bronchospasm,
which may be life threatening. If paradoxical bronchospasm occurs
following dosing with Advair Diskus, it should be treated immediately
with an inhaled, short-acting bronchodilator, Advair Diskus should
be discontinued immediately, and alternative therapy should be instituted.
9. Immediate Hypersensitivity Reactions: Immediate hypersensitivity
reactions may occur after administration of Advair Diskus, as demonstrated
by cases of urticaria, angioedema, rash, and bronchospasm.
10. Upper Airway Symptoms: Symptoms of laryngeal spasm, irritation,
or swelling, such as stridor and choking, have been reported in
patients receiving fluticasone propionate and salmeterol, components
of Advair Diskus.
11. Cardiovascular Disorders: Advair Diskus, like all products containing
sympathomimetic amines, should be used with caution in patients
with cardiovascular disorders, especially coronary insufficiency,
cardiac arrhythmias, and hypertension. Salmeterol, a component of
Advair Diskus, can produce a clinically significant cardiovascular
effect in some patients as measured by pulse rate, blood pressure,
and/or symptoms. Although such effects are uncommon after administration
of salmeterol at recommended doses, if they occur, the drug may
need to be discontinued. In addition, beta-agonists have been reported
to produce ECG changes, such as flattening of the T wave, prolongation
of the QTc interval, and ST segment depression. The clinical significance
of these findings is unknown.
12. Discontinuation of Systemic Corticosteroids: Transfer of patients
from systemic corticosteroid therapy to Advair Diskus may unmask
conditions previously suppressed by the systemic corticosteroid
therapy, e.g., rhinitis, conjunctivitis, eczema, arthritis, and
eosinophilic conditions.
13. Immunosuppression: Persons who are using drugs that suppress
the immune system are more susceptible to infections than healthy
individuals. Chickenpox and measles, for example, can have a more
serious or even fatal course in susceptible children or adults using
corticosteroids. In such children or adults who have not had these
diseases or been properly immunized, particular care should be taken
to avoid exposure. How the dose, route, and duration of corticosteroid
administration affect the risk of developing a disseminated infection
is not known. The contribution of the underlying disease and/or
prior corticosteroid treatment to the risk is also not known. If
exposed to chickenpox, prophylaxis with varicella zoster immune
globulin (VZIG) may be indicated. If exposed to measles, prophylaxis
with pooled intramuscular immunoglobulin (IG) may be indicated.
(See the respective package inserts for complete VZIG and IG prescribing
information.) If chickenpox develops, treatment with antiviral agents
may be considered.
How to Save When Buying Advair Asthma
Medication
Advair from Canada
Advair is an expensive drug when purchased in the United States.
The reason for the expensive price in the US is because the US Government
does not regulate prices on Advair arthritis medication and therefore
Advair is most expensive when bought in the United States. There
are alternative international sources for Advair and Canada is
well known for its safe yet much more affordable rx medication.
Canada is a reliable and proven alternate source for Americans who
cannot afford Advair at American costs. The Canadian Government
regulates all drugs including Advair and so drug prices in Canada
are much cheaper. Savings of up to 90% on drugs are possible when
purchasing Advair from Canadian pharmacies.
Another factor determining the cheap prices from Canada is the US
to Canadian dollar currency exchange rate. The American dollar can
go much further when ordering prescription medications such as Advair
from Canada.
Order Advair Asthma
Medication from Canada
Q. Is it safe to order Advair Asthma
Medication from Canada?
A. Advair form Canada is as safe as Advair from the US. Take
Precautions when searching Canadian Online Pharmacies.
About Asthma
Asthma is one of the most common serious chronic diseases in the
United States. If you suffer from asthma, the more you know, the
more control you'll feel you have.
The medical definition of asthma is simple, but the condition itself
is quite complex.
Asthma is a chronic disease of the airways of your lungs. These
airways are also known as bronchial tubes. In the case of asthma,
chronic means that it never goes away.
Asthma is one disease that has two main components occurring deep
within the airways of your lungs:
• Inflammation. The airways of the lungs are always inflamed
if you have asthma, and become more swollen and irritated when an
attack begins. Your healthcare professional may refer to this swelling
and irritation as "inflammation." Inflammation can reduce
the amount of air that you can take in or breathe out of your lungs.
In some cases, the mucus glands in the airways produce excessive,
thick mucus, further obstructing the airways.
• Constriction. The muscles around the airways in the lungs
squeeze together or tighten. This tightening is often called "bronchoconstriction,"
and it can make it hard for you to breathe the air in or out of
your lungs.
Inflammation and constriction together cause narrowing of the airways,
which can result in wheezing, chest tightness, or shortness of breath.
In people with asthma, the airways are inflamed even when you're
not having symptoms.
Antidepressant
Medication and Information - Lexapro
Side Effects - Paxil
Side Effects - Paxil
CR Side Effects - Zoloft
Side Effects - Arthritis
Medication and Information - Arcoxia
Side Effects- Celebrex
Side Effects - Mobic
Side Effects - Vioxx
Side Effects - Asthma
Medication and Information - Advair
Side Effects - Cholesterol
Medication and Information - Advicor
Side Effects - Crestor
Side Effects -
Lescol Side Effects - Lipitor
Side Effects - Pravachol
Side Effects - Zetia
Side Effects - Zocor
Side Effects - Epilepsy
Medication and Information - Neurontin
Side Effects - Osteoporosis
Medication and Information - Actonel
Side Effects - Fosamax
Side Effects
Link
to Us
*Legal Disclaimer - All of the information
provided in and through this Web site is intended solely for general
information and should NOT be relied upon for any particular diagnosis,
treatment, or care. This website strongly encourages patients and
their families to consult with qualified medical professionals for
treatment advice on individual cases.
|
Discount
Canadian Pharmacy